US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
pharma · Parkinson Disease · Tuberculosis · GANX
Gain Therapeutics
Gain Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Bethesda, USA HQ
2017 Founded
28 Employees
Public company Type
GANX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Bethesda, USA
- Founded
- 2017
- Employees
- 28
- Programs
- 4
- Drugs
- 7
- Patents
- 27
Gain Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Gain Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Gain Therapeutics in public FDA and regional records.
-
Development asset linked to Gain Therapeutics in public FDA and regional records.
-
germanium (68ge) chloride
Various (V09)Various (V09) compound in Gain Therapeutics's portfolio.
-
Development asset linked to Gain Therapeutics in public FDA and regional records.
-
Development asset linked to Gain Therapeutics in public FDA and regional records.
-
Various (V04) compound in Gain Therapeutics's portfolio.